Is PRTC or PTGX more undervalued in 2026?

CirclFi compares PureTech Health plc (PRTC) and Protagonist Therapeutics, Inc. (PTGX) using 13 institutional-grade valuation models. PRTC has a Quality of Company score of 5.4/10 while PTGX scores 7.4/10.

Which is a better buy — PRTC or PTGX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PRTC and PTGX valuations compare?

PRTC at $17.25 and PTGX at $99.56 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PRTC vs PTGX Valuation Comparison 2026 — Intrinsic Value Analysis

PRTC

Pharmaceutical Preparations

PureTech Health plc

Quality

5.4

out of 10

Value Trap

LOW

Price

$17.25

Last close

Models

12/13

Active

PTGX

Pharmaceutical Preparations

Protagonist Therapeutics, Inc.

Quality

7.4

out of 10

Value Trap

SAFE

Price

$99.56

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	PRTC Fair Value	PRTC Upside	PTGX Fair Value	PTGX Upside
Bayesian DCF	Intrinsic	$19.06	+10.5%	$32.65	-67.2%
Earnings Power Value	Intrinsic	$2.12	-88.3%	$43.68	-56.3%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PRTC vs PTGX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PRTC vs PTGX — Which Stock Is More Undervalued?

PTGX scores higher with a 7.4/10 quality rating vs PRTC's 5.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing PureTech Health plc (PRTC) and Protagonist Therapeutics, Inc. (PTGX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PRTC currently trades at $17.25 with a QOC of 5.4/10, while PTGX trades at $99.56 with a QOC of 7.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).